Extended-release trazodone in the treatment of major depressive disorder

被引：0

作者：

Karamustafalioglu, Oguz ^{[1
]}

Dilbaz, Nesrin ^{[2
]}

Caykoylu, Ali ^{[3
]}

Alkin, Tunc ^{[4
]}

Gonul, Ali Saffet ^{[5
]}

Atmaca, Murad ^{[6
]}

机构：

[1] Adli Tip Kurumu, Istanbul, Turkey

[2] Uskudar Univ, ITBF Psikol Bolumu, Istanbul, Turkey

[3] Ankara Yildirim Beyazit Univ, Psikiyatri & Davranissal Norobilim Uygulama & Ara, Ankara, Turkey

[4] Dokuz Eylul Univ, Tip Fak, Psikiyatri ABD, Izmir, Turkey

[5] Ege Univ, Tip Fak, Psikiyatri ABD, Izmir, Turkey

[6] Firat Univ, Tip Fak, Psikiyatri ABD, Elazig, Turkey

来源：

ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY | 2019年 / 20卷 / 05期

关键词：

major depressive disorder; extended-release trazodone (single dose of TzCOAD per day); immediate-release trazodone (three doses of TzIR per day); PROLONGED-RELEASE; TOLERABILITY; EFFICACY;

D O I：

10.5455/apd.302644467

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Major depressive disorder is a common psychiatric disorder. The aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). In this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants.

引用

页码：453 / 459

页数：7

共 50 条

[21] Levomilnacipran Extended-Release: A Review of Its Use in Adult Patients with Major Depressive Disorder
Lesley J. Scott
CNS Drugs, 2014, 28 : 1071 - 1082
[22] Effects of Quetiapine Extended-Release on Sleep and Quality of Life in Midlife Women With Major Depressive Disorder
Frey, Benicio N.
Haber, Erika
Mendes, Gustavo C.
Steiner, Meir
Soares, Claudio N.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2011, 18 (12): : 1371 - 1371
[23] Gepirone: A New Extended-Release Oral Selective Serotonin Receptor Agonist for Major Depressive Disorder
Phillips, Bradley
O'Connor, Colin
St. Onge, Erin
JOURNAL OF PHARMACY TECHNOLOGY, 2024, 40 (05) : 230 - 235
[24] Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder
Siwek, Marcin
Chrobak, Adrian Andrzej
Krupa, Anna Julia
Gorostowicz, Aleksandra
Juryk, Andrzej
Dudek, Dominika
FRONTIERS IN PHARMACOLOGY, 2025, 15
[25] Long-term, open-label venlafaxine extended-release treatment in children and adolescents with major depressive disorder
Emslie, Graham J.
Yeung, Paul P.
Kunz, Nadia R.
CNS SPECTRUMS, 2007, 12 (03) : 223 - 233
[26] Gepirone extended-release treatment of anxious depression: Evidence from a retrospective subgroup analysis in patients with major depressive disorder
Alpert, JE
Franznick, DA
Hollander, SB
Fava, M
JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (08) : 1069 - 1075
[27] Extended-release carbamazepine for the treatment of bipolar disorder
Ginsberg, LD
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2004, 14 (04) : 517 - 518
[28] Venlafaxine extended-release treatment of hoarding disorder
Saxena, Sanjaya
Sumner, Jennifer
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (05) : 266 - 273
[29] TED-trazodone effectiveness in depression: a naturalistic study of the effeciveness of trazodone in extended release formulation compared to SSRIs in patients with a major depressive disorder
Dudek, Dominika
Chrobak, Adrian Andrzej
Krupa, Anna Julia
Gorostowicz, Aleksandra
Gerlich, Adrian
Juryk, Andrzej
Siwek, Marcin
FRONTIERS IN PHARMACOLOGY, 2023, 14
[30] Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder
Trivedi, MH
Wan, GJ
Mallick, R
Chen, JL
Casciano, R
Geissler, EC
Panish, JM
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (05) : 497 - 506

← 1 2 3 4 5 →